A 24-year-old man came to a clinic with three days of intermittent abdominal pain and fever. His abdomen was soft. He was tender in the upper middle and left flank, with some guarding. Nothing about the presentation pointed to anything unusual.
An ultrasound revealed a gaseous abdomen, mild enlargement of the liver and spleen, and three fluid collections within his pancreas, separated by internal walls, located in the uncinate process and the body of the organ. These looked like pseudocysts, a known consequence of pancreatitis. Doctors placed a pigtail catheter and drained one.
What came out was pus, and what grew from it was Burkholderia cenocepacia.
The case, titled as one of acute interstitial pancreatitis with a Burkholderia pseudocyst in an immunocompetent host, was published in IDCases by Shivam Thaker, Raviraj V. Acharya, and colleagues at Kasturba Medical College in Manipal, India.
This Is Not What Grows in Infected Pancreatic Fluid
Pancreatic pseudocysts form after pancreatitis and are walled-off pockets of fluid without a true epithelial lining. Most are sterile. When they do become infected, the culprits are predictable gut organisms: E. coli, Klebsiella, Enterobacter, and Enterococcus, with occasional Pseudomonas, staphylococci, or anaerobes.
Burkholderia cenocepacia belongs to a different world. The Burkholderia cepacia complex is a group of more than 20 closely related species best known to cystic fibrosis clinicians, where colonization carries a notoriously poor prognosis, and to specialists treating chronic granulomatous disease. It is an opportunist, and the textbook opportunity is a compromised immune system.
This patient had no such condition. He was immunocompetent, and the authors present his case precisely because this combination is atypical, suggesting that the organism's elevated endotoxin-like lipopolysaccharide activity is relevant to how it behaved once inside.
A separate case in Cureus documented a multidrug-resistant Burkholderia cepacia pseudocyst infection alongside two Candida species in a 45-year-old with recent acute pancreatitis. That patient presented with hypoglycemia, altered mental status, and worsening epigastric pain, a picture no clinician would immediately connect to a waterborne environmental organism. Cases like these are rare enough to be individually reportable.
Where This Organism Usually Makes News
For US readers, the Burkholderia cepacia complex is more familiar as a manufacturing problem than a bedside one.
These bacteria thrive in water. They metabolize an unusually wide range of substrates, sometimes including the very antimicrobials meant to control them, survive on very little, and resist many of the antibiotics and antiseptics that are supposed to keep products clean. A complex genome spread across three chromosomes and a high capacity for rapid mutation round out the profile. A review in Clinical Microbiology Reviews notes that FDA recall data from 1998 to 2006 identified B. cepacia as the cause of 22 percent of non-sterile product recalls.
The agency has acted repeatedly. In late 2016, the FDA and CDC found the organism in a water system used to make oral liquid docusate sodium, triggering a national alert and recall; that outbreak involved 63 confirmed and 45 suspected infections across 12 states. A second multistate outbreak the following year prompted the FDA to advise against using any liquid drug product from the manufacturer involved. A separate outbreak was traced to a no-rinse cleansing foam used for patient skin care in healthcare facilities.
None of that means this patient's infection came from a product. His source was not established, and the report does not claim one. It does explain why an organism this obscure to the public is well known to regulators.
What This Does Not Mean
One thing this case is not evidence of is that healthy people are at meaningful risk from this organism. Serious Burkholderia infections remain concentrated among patients with cystic fibrosis, immune deficiencies, or recent exposure to contaminated medical products, and a single case report cannot change that picture.
What it does is widen a differential. Infected pancreatic collections are usually assumed to be seeded by gut flora, and empirical antibiotics are chosen on that assumption. This patient's culture is a reminder that the assumption is a starting point, not an answer.
Why Naming the Bug Changed the Treatment
Identification was not academic. Burkholderia species carry intrinsic resistance to a range of antibiotics and antiseptics, so an empirical regimen aimed at gut bacteria could easily have missed.
Mass spectrometry of growth from blood and MacConkey agar provided a species-level identification, and susceptibility testing showed the isolate was sensitive to ceftazidime. He was started on 21 days of intravenous ceftazidime. The catheter remained in place until drainage fell below 10 milliliters per day for three consecutive days, and he was discharged in good condition.
The general lesson is about sampling. Draining an infected collection is both treatment and diagnosis, and culturing the drainage turns a guess into a targeted regimen.
Anyone recovering from pancreatitis who develops a new fever, worsening abdominal pain, persistent vomiting, or a swelling in the upper abdomen should be evaluated promptly rather than waiting it out. Pseudocysts often settle on their own, but an infected one will not, and the only way to know which is which is to look.
Key Questions Answered
What is a pancreatic pseudocyst?
A walled-off collection of fluid that forms near or within the pancreas after pancreatitis. Many resolve on their own, but they can become infected, rupture or press on nearby organs.
What made this case unusual?
The infecting organism. Burkholderia cenocepacia is associated with cystic fibrosis and immune disorders, not pancreatic fluid collections, and this patient had a normal immune system.
Where does this bacterium come from?
It is widespread in water and soil. It is notorious for surviving in pharmaceutical water systems and non-sterile, water-based products, which has led to repeated FDA recalls.
Did the patient get it from a contaminated product?
The report does not identify a source, and no product link was established. The regulatory history explains why the organism is well documented, not how this particular infection occurred.
Why does identifying the exact organism matter?
Burkholderia species resist many antibiotics that would cover typical gut bacteria. Naming the isolate and testing its susceptibility is what allowed a regimen likely to work.
What symptoms should prompt care after pancreatitis?
New or returning fever, worsening abdominal pain, persistent vomiting, or a palpable upper abdominal swelling. Anyone with these should be assessed by a clinician promptly.
